Moreover, consistent with recent studies in esophageal cancer and lung cancer, we found that high expression of DLEU2 was related to more advanced T stage and N stage and higher Gleason scores in prostate cancer and that DLEU2 upregulation was associated with poor survival rates. The gene discussed is DLEU2; the disease is prostate carcinoma.